Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast Cancer

Mohammad Jahanzeb, MD
Published: Wednesday, Mar 22, 2017



Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

The mainstay of this disease is HER2 blockade, says Jahanzeb. The future of adjuvant therapy, he adds, is not just a single HER2-targeted agent, but either dual antibody or an antibody followed by a small molecule tyrosine kinase inhibitor.

The chemotherapy that is combined with this is less important, and patients with smaller tumors will not need to be administered combination chemotherapy, says Jahanzeb.
 


Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

The mainstay of this disease is HER2 blockade, says Jahanzeb. The future of adjuvant therapy, he adds, is not just a single HER2-targeted agent, but either dual antibody or an antibody followed by a small molecule tyrosine kinase inhibitor.

The chemotherapy that is combined with this is less important, and patients with smaller tumors will not need to be administered combination chemotherapy, says Jahanzeb.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x